The Number, Quality, and Coverage of Randomized Controlled Trials in Nephrology
Top Cited Papers
- 1 February 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 15 (2) , 411-419
- https://doi.org/10.1097/01.asn.0000100125.21491.46
Abstract
Randomized controlled trials (RCT) are the optimal study design to answer intervention questions. The authors evaluated the number, quality, and coverage of RCT in nephrology. MEDLINE was searched using the relevant medical subject headings for nephrology and 12 major specialties in internal medicine, limited by “randomized controlled trial” as a publication type. A random selection of 160 RCT in nephrology (40 for each decade) published since 1966 and an additional 270 RCT from ongoing or published Cochrane systematic reviews in various areas of nephrology, dialysis, and transplantation were evaluated for quality of reporting using standard criteria. The number of RCT published in nephrology from 1966 to 2002 (2779) is fewer than all other specialties of internal medicine (range: 5335 in hematology to 27109 in cardiology) with the proportion of all citations which are RCT being the third lowest (1.15%). There has been an increase in both indices from 1966 to 1996, but not at a greater rate than other specialties, and there has been no increase over the past 5 yr. Some areas of nephrology, in particular glomerulonephritis, are clear outliers with very low numbers of RCT to guide clinical decision-making. Overall the quality of RCT reporting in nephrology is low and has not improved over the past 30 yr with unclear allocation concealment (89%), lack of reported blinding of outcome assessors (92%), and failure to perform “intention-to-treat analysis” (50%) particularly frequent. The challenges of improving the quality and quantity of trials in nephrology are substantial, but they can be overcome by using standard guidelines and checklists for trial reporting, greater attention to the trial methods and not just the results, involving experts in trial design and reporting, multicenter collaboration, and larger and simpler trials.Keywords
This publication has 16 references indexed in Scilit:
- Central Challenges Facing the National Clinical Research EnterpriseJAMA, 2003
- Fewer new drugs from the pharmaceutical industryBMJ, 2003
- Scope and Impact of Financial Conflicts of Interest in Biomedical ResearchJAMA, 2003
- Clinical Research Career DevelopmentAcademic Medicine, 2002
- Cochrane Renal Group reportAmerican Journal of Kidney Diseases, 2002
- How Well Are Randomized Controlled Trials Reported in the Dermatology Literature?Archives of Dermatology, 2000
- Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Published by Elsevier ,1998
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Empirical Evidence of BiasJAMA, 1995
- A Study of the Status of Clinical Cancer Research in the United States (1990)JNCI Journal of the National Cancer Institute, 1991